ArticleInternational journal of general medicine2025
Serum LCAT as a Gender-Neutral Biomarker for Early Osteoporosis: A Multicenter Cohort Validation Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to identify a novel biomarker for the early detection and prevention of osteoporosis. Methods: A cross-sectional study (n=138, from 497 screened) was conducted at Nanjing Drum Tower Hospital (Sep 2023-Jun 2024). A second multicenter validation cohort (n=165) was collected (Jun 2024-Jan2025) from three hospitals, including 90 controls, 35 osteopenia, and 40 OP cases. Serum LCAT was measured via ELISA. Statistical analyses ( Results: Serum LCAT levels were significantly lower in both the osteopenia (n=32, p<0.01) and osteoporosis groups (n=50, p<0.001) compared with control group (n=56). The results from this second cohort support our previous cross-sectional findings, serum LCAT levels in controls (44.41 ± 14.16), osteopenia (32.15 ± 8.93) and osteoporosis (22.15 ± 7.07). In this multicenter study, serum LCAT levels were evaluated and found to be significantly decreased in the primary osteoporosis group compared to controls across all populations with notable differences by sex (males: U=207.5, p=0.0031; females: U=520.5, p=0.0001) and age (≤55 years: p=0.005; >55 years: p=0.0001). LCAT levels showed positive correlations with T/Z-scores, BMI, ALT, AST, LDL-C, and serum phosphorus, and negative correlations with age and serum creatinine. ROC analysis yielded an AUC of 0.822, with sensitivity and specificity of 75.9% and 78%, respectively. Moreover, serum LCAT levels exhibited significantly higher predictive value for osteoporosis than that of conventional serum 25-hydroxyvitamin D (25OHD) levels. Conclusion: We demonstrate for the first time that reduced serum LCAT concentrations predict osteoporosis risk independently of confounding factors, qualifying it as a promising early-stage diagnostic biomarker. These findings establish LCAT as a demography-invariant diagnostic biomarker for early-stage osteoporosis, suggesting its potential utility in population-wide screening programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.